Clinical Trials Browser

Phase 2 × Disease Progression × marizomib × Clear all

NCT03727841 2022-07-27

Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma

Phase 2 Terminated

4 enrolled 13 charts

Ependymoma, Disease Progression